Leslie Cho

Leslie Cho

Auto-generated profile, based on publicly available information

Leslie Cho

Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in JACC
Verified
Journal Article
Closed access
LCLeslie Cho
Leslie Cho
MDMelinda Davis
Melinda Davis
IEIslam Elgendy
Islam Elgendy
KEKelly Epps
Kelly Epps
KLKathryn J. Lindley
Kathryn J. Lindley
AVAnnabelle Santos Volgman
Annabelle Santos Volgman

14 February 2023 in Circulation
Verified
Journal Article
Closed access
LCLeslie Cho
Leslie Cho
AKAndrew M. Kaunitz
Andrew M. Kaunitz
SFStephanie S. Faubion
Stephanie S. Faubion
SHSharonne N. Hayes
Sharonne N. Hayes
ELEmily S. Lau
Emily S. Lau
FCfor the ACC CVD in Women Committee
for the ACC CVD in Women Committee
Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.

1 September 2013 in American Heart Journal
Verified
Journal Article
Closed access
WMWarner M. Mampuya
Warner M. Mampuya
DFDavid Frid
David Frid
MRMichael Rocco
Michael Rocco
JHJulie Huang
Julie Huang
DBDanielle M. Brennan
Danielle M. Brennan
LCLeslie Cho
Leslie Cho

1 August 2021 in JACC
Verified
Journal Article
Closed access
LCLeslie Cho
Leslie Cho
AVAmanda R. Vest
Amanda R. Vest
MOMichelle L. O’dOnoghue
Michelle L. O’dOnoghue
MOModele O. Ogunniyi
Modele O. Ogunniyi
ASAmy A. Sarma
Amy A. Sarma
RMRoxana Mehran
Roxana Mehran

18 February 2025 in Circulation
Verified
Journal Article
Closed access
MCMalamo Countouris
Malamo Countouris
ZMZainab Mahmoud
Zainab Mahmoud
JCJordana B. Cohen
Jordana B. Cohen
DCDaniela Crousillat
Daniela Crousillat
AHAfshan B. Hameed
Afshan B. Hameed
NBNatalie A. Bello
Natalie A. Bello
Hypertension in pregnancy contributes substantially to maternal morbidity and mortality, persistent hypertension, and rehospitalization. Hypertensive disorders of pregnancy are also associated with a heightened risk of cardiovascular disease, and timely recognition and modification of associated risk factors is crucial in optimizing long-term maternal health. During pregnancy, there are expected physiologic alterations in blood pressure (BP); however, pathophysiologic alterations may also occur, leading to preeclampsia and gestational hypertension. The diagnosis and effective management of hypertension during pregnancy is essential to mitigate maternal risks, such as acute kidney injury, stroke, and heart failure, while balancing potential fetal risks, such as growth restriction and preterm birth due to altered uteroplacental perfusion. In the postpartum period, innovative and multidisciplinary care solutions that include postpartum maternal health clinics can help optimize short- and long-term care through enhanced BP management, screening of cardiovascular risk factors, and discussion of lifestyle modifications for cardiovascular disease prevention. As an adjunct to or distinct from postpartum clinics, home BP monitoring programs have been shown to improve BP ascertainment across diverse populations and to lower BP in the months after delivery. Because of concerns about pregnant patients being a vulnerable population for research, there is little evidence from trials examining the diagnosis and treatment of hypertension in pregnant and postpartum individuals. As a result, national and international guidelines differ in their recommendations, and more studies are needed to bolster future guidelines and establish best practices to achieve optimal cardiovascular health during and after pregnancy. Future research should focus on refining treatment thresholds and optimal BP range peripartum and postpartum and evaluating interventions to improve postpartum and long-term maternal cardiovascular outcomes that would advance evidence-based care and improve outcomes worldwide for people with hypertensive disorders of pregnancy.

30 January 2014 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
AVAmanda R. Vest
Amanda R. Vest
LCLeslie S. Cho
Leslie S. Cho